Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Marijuana smoking vs cannabinoids for glaucoma therapy

K Green1

  • 1Department of Ophthalmology, Medical College of Georgia, Augusta, USA. kgreen@mail.mcg.edu

Archives of Ophthalmology (Chicago, Ill. : 1960)
|November 21, 1998
PubMed
Summary

Marijuana lowers intraocular pressure (IOP) but smoking it for glaucoma is ill-advised due to systemic toxicity. Developing cannabinoid-based glaucoma drugs is promising.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.

Transplant infectious disease : an official journal of the Transplantation Society·2005
Same author

Health literacy and patient knowledge in a Southern US HIV clinic.

International journal of STD & AIDS·2004
Same author

Effects of instructions on physical capacities outcome in a workers' compensation setting.

Pain medicine (Malden, Mass.)·2004
Same author

Improved glucose homeostasis in mice overexpressing human UCP3: a role for AMP-kinase?

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity·2004
Same author

Association of human leukocyte antigen with outcomes of infectious diseases: the streptococcal experience.

Scandinavian journal of infectious diseases·2003
Same author

Changes in EBV gene load in renal transplant recipients.

Transplantation proceedings·2003

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Toxicology

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma.
  • Marijuana and its compounds have been investigated for potential therapeutic effects in glaucoma management.

Purpose of the Study:

  • To review the clinical effects and toxicological data of marijuana and cannabinoids on ocular and systemic health.
  • To provide a perspective on the use of marijuana and cannabinoids for glaucoma treatment.

Main Methods:

  • Literature review and synthesis of existing clinical and toxicological data.
  • Analysis of the effects of marijuana and cannabinoids on intraocular pressure and systemic health.
  • Evaluation of the therapeutic potential and risks associated with cannabinoid-based glaucoma treatments.

Main Results:

  • Smoking marijuana causes a temporary reduction in IOP in 60-65% of users.
  • Sustained use of marijuana for IOP control leads to significant systemic toxic effects and pathological changes.
  • Cannabinoid compounds offer potential for developing novel glaucoma medications.

Conclusions:

  • While marijuana smoking lowers IOP, its systemic toxicity makes it unsuitable for chronic glaucoma management.
  • Developing pharmaceutical agents based on cannabinoid molecules, particularly those without psychoactive side effects, warrants further investigation for topical or oral antiglaucoma therapies.

Related Experiment Videos